ScreenerHero

BDSX Biodesix, Inc.

NAS · US · Healthcare · Diagnostics & Research · biodesix.com
26.42USD-5.51%Mkt Cap: 278.76M $P/E: —

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of …

Industry Peers

Diagnostics & Research
Screen all
TMO
Thermo Fisher Scientific Inc.
$244.79BUSDP/E 36.7
DHR
Danaher Corporation
$153.60BUSDP/E 38.9
NTRA
Natera, Inc.
$57.02BUSD
LONN
Lonza Group AG
$46.01BUSDP/E 38.3
A
Agilent Technologies, Inc.
$47.67BUSDP/E 33.4
WAT
Waters Corporation
$42.81BUSDP/E 110.4
IQV
IQVIA Holdings Inc.
$42.48BUSDP/E 32.1
ILMN
Illumina, Inc.
$40.43BUSDP/E 50.0
IDXX
IDEXX Laboratories, Inc.
$39.97BUSDP/E 35.6
MTD
Mettler-Toledo International Inc.
$30.73BUSDP/E 34.6
LH
Labcorp Holdings Inc.
$25.30BUSDP/E 25.8
DGX
Quest Diagnostics Incorporated
$25.06BUSDP/E 24.1
GH
Guardant Health, Inc.
$22.59BUSD
RVTY
Revvity, Inc.
$17.14BUSDP/E 73.5
MEDP
Medpace Holdings, Inc.
$16.87BUSDP/E 35.5
ERF
Eurofins Scientific SE
$14.23BUSDP/E 26.6
CRL
Charles River Laboratories International, Inc.
$14.34BUSD
ICLR
ICON Public Limited Company
$12.66BUSDP/E 172.7
BIM
bioMérieux S.A.
$10.35BUSDP/E 20.7
QGEN
Qiagen N.V.
$9.25BUSDP/E 22.7

Key Statistics

Company
Market Cap278.76M USD
Enterprise Value336.81M USD
Revenue (TTM)102.94M USD
Gross Profit71.78M USD
Net Income (TTM)-35.27M USD
Revenue/Share11.59 USD
Last Price26.42 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees334
CountryUS
SectorHealthcare
IndustryDiagnostics & Research
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-127.09
PEG—
EV/EBITDA-22.45
EV/Revenue3.27
P/S2.87
P/B32.25
EPS (TTM)-3.10
EPS (Forward)-0.22
52W Range
5.26079% of range31.97
52W High31.97 USD
52W Low5.260 USD
Profitability
Gross Margin81.11%
Oper. Margin-20.01%
EBITDA Margin-14.58%
Profit Margin-39.85%
ROE1430.63%
ROA-40.31%
Growth
Revenue Growth34.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.27M USD
CapEx (TTM)403.00K USD
FCF Margin-10.58%
FCF Yield-3.91%
Net Debt41.80M USD
Net Debt/EBITDA-2.79
Balance Sheet
Debt/Equity-29.56
Current Ratio2.85
Quick Ratio2.56
Book Value/Sh0.87 USD
Cash/Share2.84 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:20
Split DateSep 15, 2025
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)37.33 USD
Upside (mean)+41.3%
Target Range30.00 USD – 41.00 USD
30.00+41.3% to mean41.00
# Analysts6
Ownership
Shares Out.10.55M
Float4.98M
Insiders40.15%
Institutions41.41%
Short Interest
Short Ratio1.8d
Short % Float3.51%
Short % Out.2.03%
Shares Short214.01K
Short (prev mo.)150.09K
Technical
SMA 5025.98 (+1.7%)
SMA 20017.03 (+55.1%)
Beta0.55
S&P 52W Chg16.45%
Avg Vol (30d)117.52K
Avg Vol (10d)133.78K
Technical Indicators
RSI (14)46.5
MACD0.6741
MACD Signal1.0752
MACD Hist.-0.4010
BB Upper30.62 USD
BB Middle28.16 USD
BB Lower25.71 USD
BB Width17.45%
ATR (14)2.297 USD
Vol Ratio (20d)0.55x